Replies to post #233308 on Biotech Values

[DewDiligence]

AKUS -34% on no news I’m aware of.

The stock is down 82% from its 2020 IPO (#msg-156532797).

[DewDiligence]

LLY acquires AKUS for $12.50/sh cash—a 78% premium to yesterday’s close:

https://finance.yahoo.com/news/lilly-acquire-akouos-discover-develop-105000897.html

The deal includes a non-tradeable CVR that pays $1.00/sh for each of three contingencies (i.e. $3.00/sh maximum). The nominal deal value (excluding the CVR) is $487M.

AKUS is pursuing gene therapy for hearing conditions. The buyout price is 26% below AKUS’s 2020 IPO price of $17.00 (#msg-156532797).